A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,015,000 shares of CTMX stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,015,000
Previous 1,183,022 14.2%
Holding current value
$1.09 Million
Previous $1.44 Million 17.05%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.12 - $1.51 $188,184 - $253,713
-168,022 Reduced 14.2%
1,015,000 $1.2 Million
Q2 2024

Aug 09, 2024

SELL
$1.21 - $5.13 $60,231 - $255,361
-49,778 Reduced 4.04%
1,183,022 $1.44 Million
Q1 2024

May 13, 2024

SELL
$1.41 - $2.74 $130,988 - $254,546
-92,900 Reduced 7.01%
1,232,800 $2.69 Million
Q4 2023

Feb 13, 2024

BUY
$1.07 - $1.55 $423,292 - $613,180
395,600 Added 42.53%
1,325,700 $2.06 Million
Q3 2023

Nov 14, 2023

SELL
$1.26 - $1.87 $242,298 - $359,601
-192,300 Reduced 17.13%
930,100 $1.2 Million
Q2 2023

Aug 11, 2023

BUY
$1.41 - $1.92 $383,661 - $522,432
272,100 Added 32.0%
1,122,400 $1.93 Million
Q1 2023

May 12, 2023

SELL
$1.48 - $2.88 $725,901 - $1.41 Million
-490,474 Reduced 36.58%
850,300 $1.28 Million
Q4 2022

Feb 13, 2023

SELL
$1.19 - $1.91 $553,142 - $887,817
-464,826 Reduced 25.74%
1,340,774 $2.15 Million
Q3 2022

Nov 14, 2022

BUY
$1.23 - $1.97 $432,146 - $692,137
351,339 Added 24.16%
1,805,600 $2.62 Million
Q2 2022

Aug 12, 2022

BUY
$1.53 - $2.89 $854,292 - $1.61 Million
558,361 Added 62.32%
1,454,261 $2.66 Million
Q1 2022

May 13, 2022

BUY
$2.67 - $4.68 $1.04 Million - $1.83 Million
390,400 Added 77.23%
895,900 $2.39 Million
Q4 2021

Feb 11, 2022

SELL
$3.87 - $7.39 $1.51 Million - $2.88 Million
-389,100 Reduced 43.49%
505,500 $2.19 Million
Q3 2021

Nov 12, 2021

SELL
$4.32 - $6.43 $568,512 - $846,188
-131,600 Reduced 12.82%
894,600 $4.55 Million
Q2 2021

Aug 13, 2021

SELL
$6.33 - $9.91 $2.7 Million - $4.23 Million
-426,368 Reduced 29.35%
1,026,200 $6.5 Million
Q1 2021

May 13, 2021

SELL
$6.6 - $9.0 $4.04 Million - $5.51 Million
-611,932 Reduced 29.64%
1,452,568 $11.2 Million
Q4 2020

Feb 10, 2021

SELL
$6.47 - $7.9 $1.55 Million - $1.9 Million
-240,100 Reduced 10.42%
2,064,500 $13.5 Million
Q3 2020

Nov 13, 2020

SELL
$6.55 - $8.83 $301,765 - $406,806
-46,071 Reduced 1.96%
2,304,600 $15.3 Million
Q2 2020

Aug 13, 2020

BUY
$7.4 - $14.64 $1.06 Million - $2.09 Million
142,671 Added 6.46%
2,350,671 $19.6 Million
Q1 2020

May 14, 2020

BUY
$3.61 - $8.6 $522,471 - $1.24 Million
144,729 Added 7.01%
2,208,000 $16.9 Million
Q4 2019

Feb 13, 2020

BUY
$5.17 - $8.91 $2.75 Million - $4.73 Million
530,971 Added 34.65%
2,063,271 $17.1 Million
Q3 2019

Nov 13, 2019

BUY
$7.38 - $12.25 $924,714 - $1.53 Million
125,300 Added 8.91%
1,532,300 $11.3 Million
Q2 2019

Aug 12, 2019

BUY
$9.35 - $11.41 $1.09 Million - $1.33 Million
116,400 Added 9.02%
1,407,000 $15.8 Million
Q1 2019

May 14, 2019

SELL
$9.5 - $19.16 $258,400 - $521,152
-27,200 Reduced 2.06%
1,290,600 $13.9 Million
Q4 2018

Feb 13, 2019

BUY
$12.69 - $18.61 $16.7 Million - $24.5 Million
1,317,800 New
1,317,800 $19.9 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $70.6M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.